天臣医疗(688013) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥62,133,105.74, representing a year-on-year increase of 15.68%[2] - The net profit attributable to shareholders for the same period was ¥12,668,757.40, an increase of 10.31% compared to the previous year[2] - The net profit after deducting non-recurring gains and losses was ¥10,318,888.20, up 14.58% year-on-year[2] - The basic earnings per share for the period was ¥0.16, an increase of 14.29% year-on-year[2] - The diluted earnings per share was ¥0.15, a decrease of 13.33% compared to the previous year[3] - The company achieved a revenue of 168 million RMB in the first three quarters of 2022, representing a year-on-year growth of 10.07% driven by domestic bulk procurement and expansion into overseas sales regions[11] - The net profit attributable to shareholders for the first three quarters was 32 million RMB, a decrease of 12.54% compared to the previous year[11] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 27 million RMB, down 2.46% year-on-year[11] - The net profit for the first three quarters of 2022 was ¥31,792,137.04, a decrease of 12.5% from ¥36,349,565.83 in the same period of 2021[18] - The total comprehensive income for the first three quarters of 2022 was ¥31,953,731.73, compared to ¥36,463,159.96 in 2021, indicating a decline of 12.3%[19] - The total comprehensive income amounted to ¥39,112,290.17, compared to ¥36,626,017.88 in the previous year, reflecting an increase of approximately 6.8%[30] Research and Development - Research and development expenses totaled ¥8,616,102.04, accounting for 13.87% of operating revenue, a decrease of 0.79 percentage points from the previous year[3] - Research and development investment increased by 27.62% year-on-year, primarily due to higher costs associated with personnel, salaries, and materials[11] - Research and development expenses increased to ¥25,082,845.75 in 2022, compared to ¥19,654,451.01 in 2021, reflecting a growth of 27.5%[17] - The company's R&D expenses for the first three quarters of 2022 were ¥25,082,845.75, which is a 27.6% increase from ¥19,654,451.01 in the same period of 2021[29] Assets and Liabilities - The total assets at the end of the reporting period were ¥564,972,830.97, reflecting a 3.70% increase from the end of the previous year[3] - The company's total liabilities were approximately 57.08 million RMB, up from 32.71 million RMB at the end of 2021[15] - The company reported a significant increase in accounts payable, which rose to approximately 14.53 million RMB from 8.69 million RMB year-on-year[15] - The capital reserve increased to approximately 400.05 million RMB from 371.33 million RMB at the end of 2021[15] - The total assets as of September 30, 2022, amounted to ¥585,293,470.04, compared to ¥557,837,062.38 at the end of 2021, indicating a growth of 4.9%[27] - The total liabilities as of September 30, 2022, were ¥56,301,975.11, compared to ¥31,767,818.97 at the end of 2021, showing an increase of 77.5%[27] - The company's total liabilities and equity amounted to ¥564,972,830.97, an increase from ¥544,834,060.77 in the previous year[16] - The company’s retained earnings increased to ¥68,639,222.15 from ¥52,656,853.77, reflecting a growth of 30.3%[16] Cash Flow - The cash flow from operating activities for the year-to-date was ¥45,334,771.43, an increase of 8.18% year-on-year[2] - Cash flow from operating activities for the first three quarters of 2022 was ¥45,334,771.43, an increase of 8.5% from ¥41,907,766.77 in 2021[21] - The net cash flow from operating activities was ¥47,750,783.45, compared to ¥40,599,820.68 in the same period last year, representing an increase of approximately 17.3%[33] - The cash inflow from investment activities in the first three quarters of 2022 was ¥1,137,359,615.33, compared to ¥862,365,938.47 in 2021, marking a significant increase of 31.9%[21] - The net cash flow from investment activities was ¥140,388,860.64, a turnaround from a negative cash flow of -¥103,304,410.32 in the previous year[33] - The cash and cash equivalents at the end of the period were ¥224,883,005.83, significantly higher than ¥52,927,887.55 at the end of the previous period, marking an increase of 324.5%[23] - The company's cash flow from operating activities showed a positive trend, with a net increase in cash and cash equivalents of ¥151,968,383.69 compared to a decrease of -¥75,058,802.84 in the previous year[33] Shareholder Information - The company reported a total of 4,362 common shareholders at the end of the reporting period[8] - The company has implemented stock incentive plans that have impacted profit margins due to increased share-based payment expenses[11] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[29]